ISIS Files for Antisense Drug to Treat CMV Infections That Cause Blindness in AIDS Patients

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

ISIS Files for Antisense Drug to Treat CMV Infections That Cause Blindness in AIDS Patients

PR Newswire (10/27/93)

Isis Pharmaceuticals Inc. has, for the second time, filed an investigational new drug application with the Food and Drug Administration for the use of an antisense drug for the treatment of cytomegalovirus retinitis in AIDS patients. CMV retinitis is an opportunistic viral infection that occurs in up to 46 percent of people with AIDS and often causes blindness. Current therapies for CMV retinitis delay the progression of the infection for only a short while before the disease progresses and often cause side effects that render the treatment incompatible with patients. ISIS 2922, a highly sensitive antisense compound, prevents the production of a protein essential for HIV replication, and has been shown in vitro to work against strains of the virus that are resistant to current therapies. Also, ISIS 2922 may have fewer side effects. Monkey experiments indicate that the drug can be safely administered by intravitreal injection on a weekly or biweekly schedule.

931029
AD931965

Copyright © 1993 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.